ISTA Pharmaceuticals Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported net revenue of $32.0 million for the three months ended September 30, 2009, a 47% increase over net revenue for the three months ended September 30, 2008. Operating income was $5.2 million compared with an operating loss of $5.1 million in the same period of 2008. Net loss including the non-cash warrant valuation charges was $0.9 million or $0.03 basic and diluted per share as compared with a net loss of $9.6 million, or $0.29 basic and diluted per share for the same period last year. Net loss for the three quarter included $1.0 million, or $0.03 per share, in one-time non-cash charges. For the nine months, the company reported total revenue of $76.3 million compared to $54.9 million for the same period last year. Operating loss was $0.8 million, as compared with an operating loss of $25.0 million for the same period in 2008. Net loss including the non-cash warrant valuation charges was $57.2 million or $1.72 diluted and basic per share compared to $32.8 million or $0.99 diluted and basic per share for the same periods in 2008. Net product revenue for the company's four marketed products for the full-year 2009 now is expected to be $103 to $106 million. Total net revenue for full-year 2009, including net product revenue and $2.9 million from the one-time recognition of deferred revenue resulting from the previously disclosed modification of company's partnership with Otsuka, now is expected to be $106 to $109 million. The company expects to be approximately operating income breakeven in 2009. The company expects its net loss for 2009 (excluding any mark-to-market valuation adjustments relating to warrants issued in 2008) will be approximately $7 to $10 million, as its increased net revenue will offset the costs associated with launching Bepreve and expanding its sales force.

ISTA Pharmaceuticals Inc. expected to Report Fiscal Year 2009 Results on February 15, 2010. This event was calculated by Capital IQ (Created on November 3, 2009).

ISTA Pharmaceuticals Inc., Annual General Meeting, Dec 07, 2009, at 11:30 Pacific Daylight. Location: the corporate office, 15295 Alton Parkway, Irvine, CA 92618,United States. Agenda: To elect two Class III directors to serve for a term of three years expiring upon the 2012 Annual Meeting of Stockholders or until his successor is elected; to ratify the appointment of BDO Seidman, LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2009; to approve amendments to its 2004 Performance Incentive Plan which (i) increases the number of shares of common stock reserved for issuance under the plan by an additional 6,000,000 shares, (ii) changes the number of shares under the plan that may be granted as incentive stock options to 5,250,000 and (iii) changes the number of shares under the plan that may be granted as restricted stock to 750,000; to approve its 2009 Employee Stock Purchase Plan; and to transact such other business as may properly come before the meeting or any postponement or adjournment thereof.